In the quarterly report for Q2 of 23 August 2012, BioPorto announced that its
NGAL trauma patent is approved for issue by the European Patent Office (EPO)
and EPO has now published an objection filed against the granted NGAL trauma
patent. Oppositions to key patents in areas where other companies have an
interest are not unusual. Oppositions are made with the purpose of limiting
other companies’ patent rights within the respective area. 

As with previous objections to BioPorto’s NGAL cutoff patent from several major
players within the NGAL field, the objection to the trauma patent is expected.
BioPorto’s trauma patent is considered strong and the opposition to the patent
is not expected to result in changes in the obtained patent rights. An
opposition may proceed in several years, but the patent rights remain unchanged
during this process. The actual content of the oppositions and replies will be
dealt with in cooperation with BioPorto’s patent attorneys Hřiberg A/S and
mentioned in BioPortos reporting on IP rights. 


         For further information please contact:
         Thea Olesen, CEO
         Christina Thomsen, Investor Relations
         Tel. +45 45 29 00 00, e-mail investor@bioporto.com